Avalo Therapeutics, Inc. (AVTX)

Compare

5.80

-0.79

(-11.99%)

At close: April 4 at 4:00:02 PM EDT

5.53

-0.27

(-4.66%)

After hours: April 4 at 6:29:44 PM EDT

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Bo

GlobeNewswire 11 days ago

AVTX
-11.99%
COLL

BHVN
Avalo Reports 2024 Financial Results and Recent Business Updates

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business up

GlobeNewswire 17 days ago

AVTX
-11.99%
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webc

GlobeNewswire last month

AVTX
-11.99%
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. Live webcast and replay can be found under "News / Events" in the Investors

GlobeNewswire last month

AVTX
-11.99%
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. “We are thrille

GlobeNewswire 3 months ago

AVTX
-11.99%
Avalo Therapeutics initiated with a Buy at BTIG

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $40 price target The firm sees the company’s AVTX-009 as having best-in-class features that could support preferred positioning in several large indications. Avalo’s lead efforts are in hidradenitis suppurativa, where BTIG continues to expect significant reward for more active treatment options, even after key IL-17A/F inhibitors are expected to be well-established, the analyst tells investors in a

TipRanks 3 months ago

AVTX
-11.99%
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the w

GlobeNewswire 4 months ago

AVTX
-11.99%
Avalo Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference, New YorkMonday, November 18, 2024 at 3:35 PM ET Piper Sandler 36th Annual Healthcare Conference, New YorkWednesday, December 5

GlobeNewswire 4 months ago

AVTX
-11.99%
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused

GlobeNewswire 4 months ago

AVTX
-11.99%
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026 WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company’s Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to inter

GlobeNewswire 5 months ago

AVTX
-11.99%
Avalo Announces Participation in September Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDates: September 9-11, 2024A pre-recorded presentation will be made available on Monday, September 9, 2024 at 7:00 AM ET. Stifel 2024 Virtual Immunology and Inflammation SummitFireside Chat Date

GlobeNewswire 6 months ago

AVTX
-11.99%
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates

Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal OfficerCash on hand of approximately $93.4 million as of June 30, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 202

GlobeNewswire 7 months ago

AVTX
-11.99%
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Phase 2 LOTUS Trial in patients with hidradenitis suppurativa. Mittie brings to Avalo a strong combination of drug development experience through all stages of development and except

GlobeNewswire 8 months ago

AVTX
-11.99%
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, pe

GlobeNewswire 8 months ago

AVTX
-11.99%
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. “We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement earlier this year,” said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. “Paul’s deep industry experience will immediately enhance our strategic and legal comp

GlobeNewswire 9 months ago

AVTX
-11.99%
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at 11:45 AM ET on June 24, 2024 at the Oppenheimer Novel Targets in Immunology Summit in New York, NY. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on the t

GlobeNewswire 9 months ago

AVTX
-11.99%
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. “Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-00

GlobeNewswire 10 months ago

AVTX
-11.99%

Performance Overview

Return	AVTX	S&P 500 (^GSPC)
YTD	-21.94%	-13.73%
1-Year	-64.42%	-1.42%
3-Year	-99.76%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Avalo Reports 2024 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics initiated with a Buy at BTIG

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Announces Participation in September Investor Conferences

Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Performance Overview